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ABSTRACT 
The purpose of this review is giving a current update of the knowledge in this field of ocular drug delivery. The ocular drug delivery 
has been a major challenge to drug delivery scientists mainly due to its unique anatomy and physiology. One of the major problems 
encountered by the conventional ocular dosage forms include the rapid precorneal drug loss due to its nasolacrimal drainage, tear 
turnover and drug dilution resulting in poor bioavailability. These efforts lead to development of novel drug delivery dosage forms 
such as nanoparticles, liposome, ocuserts, and mucoadhesive formulations. Controlled drug delivery systems offer many advantages 
over conventional dosage forms in terms of improving drug bioavailability, reducing toxicity and decreasing dosage frequency. 
Designing noninvasive sustained drug delivery systems and exploring the feasibility of topical application to deliver drugs to the 
posterior segment may drastically improve drug delivery in the years to come.  
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INTRODUCTION 
The human eye is an organ which reacts to light and 
pressure. As a sense organ, the mammalian 
eye allows vision. Human eyes help provide a three 
dimensional, moving image, normally colored in 
daylight
1
. Rod and cone cells in the retina allow 
conscious light perception and vision including color 
differentiation and the perception of depth. The human 
eye can differentiate between about 10 million colors
 
and is possibly capable of detecting a single photon
2
. 
The eye is a complex organ with a unique anatomy and 
physiology. The structure of eye can be divided into two 
main parts: anterior segment and posterior segment, 
anterior segment of the eye occupies approximately one-
third while the remaining portion is occupied by the 
posterior segment
3
. Tissues such as cornea, conjunctiva, 
aqueous humor, iris, ciliary body and lens make up the 
anterior portion. Back of the eye or posterior segment of 
the eye include sclera, choroid, retinal pigment 
epithelium, neural retina, optic nerve and vitreous humor 
4
. The anterior and posterior segment of eye is affected 
by various vision threatening diseases. Diseases 
affecting anterior segment include, but not limited to 
glaucoma, allergic conjunctivitis, anterior uveitis and 
cataract. While, age related macular degeneration and 
diabetic retinopathy are the most prevalent diseases 
affecting posterior segment of the eye 
5
. 
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STRUCTURE OF THE EYE 
The eye is made up of 3 main parts: 
i. Eyeball 
ii. Orbit (eye socket) 
iii. Accessory (adnexal) structures 
The eyeball: The main part of the eye is the eyeball 
(also called the globe). Each eye is sphere-shaped and is 
about 2.5 cm (1 inch) in diameter 
6
. The eyeball is rich 
in blood vessels. The inside of the eyeball is filled 
mostly with a clear, jelly like fluid called vitreous 
humor. Vitreous humor fills the back (posterior) part of 
the eye. It helps support the internal structures and 
maintain the shape of the eye. The outer part of the 
eyeball is called the wall of the eye, structure of eye as 
shown in figure 01. It can be divided into 3 layers (or 
tunics): an outer, middle and inner layer (from the 
outside to the inside of the eye). 
Outer layer: The outermost layer or covering of the 
wall of the eye is made up of the sclera and cornea and is 
called the fibrous tunic. 
Sclera: The sclera is the tough, white connective tissue 
that covers most of the outside of the eyeball. The sclera 
is seen as the white portion of the eye and serves as the 
protective covering. The optic nerve and blood vessels 
pass through the sclera in the back of the eye. Muscles 
that control the movement of the eye attach to the 
sclera
7
. 
Cornea: The cornea is the clear, dome-shaped covering 
at the front of the eye that lets in light. The cornea 
covers the pupil and the iris 
8
. It does not contain any 
blood vessels. 
Middle Layer: The middle layer of the wall of the eye 
is called the vascular tunic. The uvea has 3 main parts: 
Iris: The iris is the thin, muscular, colored part of the 
eye. It is located at the front (anterior) of the eye, 
between the cornea and the lens 
9
. The iris opens and 
closes the pupil (the small central opening) to change the 
amount of light entering the eye. 
Choroid:  The choroid is a thin layer of tissue that 
contains many tiny blood vessels that supply oxygen and 
nutrients to the retina. The choroid contains many 
pigment producing cells called melanocytes 
10
. These 
cells help absorb any excess light and minimize 
reflections within the eye. 
Ciliary body: The ciliary body lies just behind the iris 
and extends forward from the choroid. It is the muscular 
ring of tissue that helps the eye focus. It changes the 
shape of the lens so it can focus on near or far objects 
11
. 
The ciliary body contains cells that make aqueous 
humor, which is the clear fluid in the front of the eye 
between the cornea and lens. 
Inner Layer: The innermost layer of the wall of the eye 
is made up of the retina or neural tunic. The retina is the 
thin layer of cells at the back of the eyeball and works 
like the film of a camera. It is made up of nerve cells 
that are sensitive to light 
12
. These cells are connected to 
the brain by the optic nerve, which sends information 
from the eye to the brain and allows us to see. 
Lens: The lens is a transparent structure in the inner part 
of the eye, which lies directly behind the cornea and iris. 
The lens changes shape to allow the eye to focus on 
objects. The lens focuses light rays on the retina 
13
. 
Orbit: The orbit (eye socket) is a bowl-shaped cavity 
made up of bone formed from the skull that contains the 
eyeball and the connective tissues surrounding the 
eyeball. The bone and connective tissues cushion and 
protect the eye. Muscles attached to the eyeball make it 
move in different directions
14
. These small muscles 
attach to the sclera near the front of the eye and to the 
bones of the orbit at the back. The orbit also contains 
nerves, fat, blood vessels and a variety of connective 
tissues.
 
Figure 1: Structure of Eye 
5
 
Accessory structures: The accessory (adnexal) 
structures of the eye include the eyelids, conjunctiva, 
caruncle and lachrymal (tear) glands, accessory 
structures of the eye as shown in figure 02. 
Eyelids: The eyelids (palpebrae) are folds of skin that 
cover and protect the eye. Muscles raise and close the 
eyelids 
15
. The eyelids contain glands, which produce an 
oily secretion that covers the tear layer and prevents 
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tears from evaporating and the eyelids from sticking 
together. 
1. The eyelid is described as having an anterior (front) 
and a posterior (back) lamella. 
2. The anterior lamella consists of skin, a layer of fatty 
connective tissue and a layer of muscle fibers. It 
helps protect the eye and regulate the amount of 
light that reaches the eye. 
3. The posterior lamella consists of a layer of muscle, 
the palpebral conjunctiva and the tarsal plates. The 
tarsal plates are 2 thick plates of dense connective 
tissue found inside each eyelid (upper and lower) 
that help form and support the eyelid. 
4. Eyelashes grow from the edges of the eyelids. They 
help protect the eye from dust and debris. 
Conjunctiva: The conjunctiva is a clear membrane 
mucous membrane. The thin, moist layer of tissue that 
lines some organs and body cavities, including the nose, 
mouth, lungs, airways, vagina and gastrointestinal (GI) 
tract. That lines the inner surface of the eyelids and the 
outer surface of the eye. The conjunctiva secretes mucus 
to lubricate the eyeball and keep it moist 
16
. Bulbar 
conjunctiva is the part of the conjunctiva that covers the 
front, outer surface of the eyeball. Forniceal conjunctiva 
is the loose fold that connects the conjunctiva membrane 
that lines the inside of the eyelid with the conjunctiva 
membrane that covers the eyeball. Palpebral (or tarsal) 
conjunctiva is part of the conjunctiva that covers the 
inner surface of the eyelids 
17
. The plica is a small fold 
of conjunctiva tissue next to the caruncle in the inside 
corner of the eye. 
Caruncle: The caruncle is the small, pinkish portion of 
the innermost corner of the eye (or inner canthus) that 
contains oil and sweat (sebaceous) glands and 
conjunctival tissue. 
 
Figure 2: Accessory structures of the eye 
6
 
Lacrimal gland: The lacrimal gland (tear gland) is the 
almond-shaped gland located at the upper, outer corner 
of each eye. The lacrimal gland secretes tears to help 
keep the surface of the eye and lining of the eyelids 
moist and lubricated 
18
. Tears help reduce friction, 
remove dust and debris from the eye and prevent 
infection. Small lacrimal ducts (lacrimal canaliculi) 
drain tears from the lacrimal gland through very tiny, 
openings (lacrimal punctum) inside the inner corner of 
each eyelid. 
Function:  
1. The eye is the organ that works with the brain to 
provide us with the sense of sight. It works much 
like a camera.  
2. The main function of the eye is to collect light and 
turn it into electric signals, which are sent to the 
brain 
19
.  
3. If we lose the vision in one eye, we continue to see 
most of what we could see before. When light enters 
the eye, it first passes through the cornea.  
4. The light then passes through the pupil, where the 
iris adjusts the amount of light entering the eye.  
5. The light then passes through the lens of the eye. 
The lens focuses light rays onto the retina, where it 
is changed into a signal that is transmitted to the 
brain by the optic nerve. 
ADVANTAGES OF OCULAR DRUG 
DELIVERY SYSTEMS 
20
 
1. Increased accurate dosing. To overcome the side 
effects of pulsed dosing produced by conventional 
systems. 
2. To provide sustained and controlled drug delivery. 
3. To increase the ocular bioavailability of drug by 
increasing the corneal contact time. This can be achieved 
by effective adherence to corneal surface. 
4. To provide targeting within the ocular globe so as to 
prevent the loss to other ocular tissues. 
5. To circumvent the protective barriers like drainage, 
lacrimation and conjunctival absorption. 
6. To provide comfort, better compliance to the patient 
and to improve therapeutic performance of drug. 
7. To provide better housing of delivery system. 
8. They can easily administered by the patient himself. 
9. They have the quick absorption and less visual and 
systemic side effects. 
10. Ocular drug delivery system has better patient 
compliance. 
DISADVANTAGES OF OCULAR DRUG 
DELIVERY SYSTEM 
21
 
1. The drug solution stays very short time in the eye 
surface. 
2. It shows poor bioavailability. 
3. Shows instability of the dissolved drug. 
4. There is a need to use preservatives. 
LIMITATIONS OF OCULAR DRUG 
DELIVERY 
21
 
1. Dosage form cannot be terminated during emergency. 
2. Interference with vision. 
3. Difficulty in placement and removal. 
4. Occasional loss during sleep or while rubbing eyes. 
Physiology of vision: Light waves travel at a speed of 
3into10
8
m/s. Light is reflected into the eyes by the 
object within the field of vision white light is the 
combination of all the colors of the visible spectrum 
22
. 
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A specific color is seen by eye when only one 
wavelength is reflected by the object and all the others 
are absorbed. In order to achieve the clear vision, light 
reflected from objects within the visual field is focused 
on to the retina of each eye. 
The processes involved in producing a clear image are 
i. Refraction of the light rays 
ii. Accommodation of the lens 
iii. Constriction of the pupil 
iv. Convergence of eyes 
v. Activation of photoreceptors 
 
Refraction of the light rays: The light rays from the 
object pass through the conjunctiva, cornea, aqueous 
humor, lens and vitreous humor in that order. All these 
structures refract the light such that it falls on the retina. 
This is called focusing. Maximum focusing is done by 
the cornea and the lens 
23
. The light then falls on the 
retina. This light is received by the photoreceptors rods 
and cones, on the retina. The absorbed light activates the 
pigments present in the rods and cones. The pigments 
are present on the membranes of the vesicles. Thus, the 
light is then converted into action potentials in the 
membranes of the vesicles. These travel as nervous 
impulses through the rod or the cone cell and reach the 
synaptic knobs. From here the impulses are transmitted 
to the bipolar nerve cells, then to the ganglions and then 
to the optic nerves. Thus the nervous impulses generated 
in the retina are carried to the brain by about a million 
neurons of the optic nerve 
24
. The vision is controlled by 
the occipital lobe at the back of the brain. The 
information received is processed and we are able to see 
the image. The image formed on the retina is inverted, as 
shown in figure 03 an over view of refraction of the light 
rays. However, the brain makes us see the image erect. 
So, though the eyes are essential for vision, any damage 
to the optic nerves also results in impairment of vision. 
 
Figure 3: Over View of refraction of the light rays 
11
 
Accommodation of lenses: Accommodation is a reflex 
action of the eye to focus the light from an object on the 
retina 
25
. The adjustment to the distance of the object is 
done by the ciliary muscles. The ciliary muscles contract 
and expand to make the lens thin and thick, respectively. 
This changes the focal length of the lens. If the object is 
far, then the focal length is increased and if the object is 
near, then the focal length is decreased. The optimal 
focal length is 6 meters or 20 ft.  
Constriction of pupil: Pupils size influences 
accommodation by controlling the amount of light the 
pupils are constricted in a dim light they are dilated, as 
shown in figure 04 constriction of pupil. If the pupils are 
dilated if the bright light, to much light enters and 
damages the sensitive retina. If the pupil is constricted in 
dim light insufficient light would enter the eye to 
activate the light sensitive pigments. The iris consists of 
one layer of circular and one radiating smooth muscle 
fibers 
26
. Contraction of the circular fibers constricts the 
pupil and contraction of the radiating fibers dilates it. 
 
Figure 4: Constriction of pupil 
15
 
Convergence of eyes: Light rays from nearby objects 
enter the two eyes at different angles and for clear vision 
they must stimulate corresponding areas of two retinas 
27
. An extrinsic muscle moves the eyes and obtains a 
clear image they rotate the eyes so that they convert on 
the object view and there is voluntary movement of the 
eyes both eyes moves and convergence is maintained. 
The eyes are focus on different objects is on different 
points of the same object.  
Activation of photo receptors: It is the process by 
which the eye detects the energy of light via 
the Photoreceptors (rods and cones). It starts when the 
photoreceptors protein absorb the photon and cause 
changes in the cell membrane`s potential, leading to 
photo transduction 
28
.  
To understand that lets have an idea about the structure 
of Photoreceptor is composed of the following parts: 
1. The axon terminal of the photoreceptor that release 
neurotransmitter is the closest part to the visual field i.e. 
Cell body which contains nucleolus and the cell 
organelles.  
2.  The inner segment: full of mitochondria to provide 
the photoreceptor by ATP 
3. The outer segment: modified cilia with large surface 
area. It contains a light absorbing protein, called opsin 
and sodium channels. The photon hits rhodopsin. And 
the process of phototransduction occurs as follows: 
1. When Rhodopsin absorbs the photon, a 
conformational change in the retinal occurs (from cis to 
Trans).  
2. This change of retinal activates a G protein that will 
from its side activate an intracellular protein that is 
called Transduction. This activation occurs in 
(amplification manner) because each G protein activates 
100 transduction. 
3. Transducin will activate an enzyme that is called 
cGMP Phosphodiesterase. 
4. Glutamate release in the synapses will stop.  
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Glutamate release stops because no more calcium ions 
will be able to enter the photoreceptor. Calcium ions are 
necessary for exocytose of glutamate into the synapse.  
Muscular control of the eyes: There are three types of 
movements associated with the eye that are due to the 
action of muscles 
29
. They are the movement of the eye, 
the change in size of the pupil and the change in 
thickness of the lens as shown in figure 05 Binocular 
and stereoscopic vision.  The movement of the eye is 
controlled by six eye muscles that attach the sclera to the 
bones lining the optic cavity. These six muscles are 
superior and inferior rectus, internal and external rectus 
and superior and inferior oblique muscles. 
 
Figure 5: Binocular and stereoscopic vision 
16
 
Associated structures: There are certain structures 
associated with the eyes and carry out, mainly, the 
function of protection 
30
. These structures are- 
Eye brows: Along the arched upper ridges of the eye 
sockets are hairs that form the eye brows. They prevent 
the dust, rain, sweat, etc from entering the eyes. 
Eye lids: Each eye in man is protected by two eyelids 
upper and lower. The upper lid moves and covers the 
eye at regular intervals. This is called blinking. This 
action protects the eye from foreign particles. In certain 
animals, like the fishes and frogs, there is a third eyelid 
called the nictitating membrane. In man, it is very small 
and vestigial.  
 
Figure 6: Secretions of lachrymal glands 
27 
Lachrymal glands: They are also called the tear glands 
as they produce secretion called tears. 
The lachrymal glands are present one on the outer upper 
border of each eye, Secretions of lachrymal glands as 
shown in figure 06. The lachrymal secretion is watery, 
alkaline and carries out the following functions 
I) cleans the eyes 
II)  keeps the eyes moist 
III) keeps the eyes free of bacteria as it contains 
bacteriolytic lysozyme 
IV) Provides nutrition to the cornea. 
Tears physiology: Tears are product of many glands in 
the eye that form the (tear film) that coats the eye 
31
. 
Tear film is composed of many layers and has many 
physiological functions. 
Layers of tear film: 
Aqueous layer: It composed of layers, electrolytes, and 
proteins. It is produced by the lachrymal gland, and 
assists in distribution of tears, and osmo regulation 
32
. 
While the proteins of the aqueous layer has a protective 
functions and other roles as follows: 
Lipocalin: a protein found in tears and has a role in 
immune response and interaction with the cancer cells. 
Lactoferrin: Has an antiviral, antifungal, and 
antibacterial activity. It also has enzymatic activity that 
possesses anticancer properties. 
Lysozymes: enzymes that have antibacterial activity. 
Lacritin: A glycoprotein that promotes tear secretion, 
and proliferation and survival of the epithelial cells.  
Lipid layer: This layer coats the aqueous layer and 
prevents the evaporation of tears and spilling them onto 
the face .It is composed of an oily liquid that is called 
sebum. Sebum   is produced by the tarsal glands.  
Ocular drug delivery routes 
33
:  
Intra vitreal: It is a route of administration of a drug or 
other substance injected with in the vitreous humor of 
the eye in which the substance is delivered in to the eye. 
Intra vitreal administration of drugs is used to treat 
various conditions of the eye, Routes of administration 
Ocular drug delivery as shown in figure 7. 
Intra cameral: The route of administration of drug with 
in a chamber, such as the anterior or posterior chamber 
of the eye. Example: anesthesia injection of an 
anesthetic agent in to the anterior chamber of the eye, 
usually during surgery. 
Peril ocular: It is the route of administration of drug 
around the eye is called peril ocular. Example: peril 
ocular steroid injection involves placement of steroid   
around the eye to treat intraocular inflammation or 
swelling of the eye. 
Suprachoroidal: The administration of the drug in the 
supra choroid region of the eye. The suprachoroidal 
space is a space lying between the sclera and the 
choroid. 
Sub conjunctiva: The route of administration of the 
drug to the mucus membrane that lines the exposed 
portion of the eyeball and inner surface of the eyelids. 
Topical: Topical administration is employed mostly in 
the form of eye drops, ointments, gels or emulsions to 
treat anterior segment diseases. It is the most preferred 
method due to the case of administration and low cost. 
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Systemic: The blood aqueous barrier and blood retinal 
barrier are the major barriers for the anterior segment 
and posterior segment ocular drug delivery respectively. 
 
Figure 7: Routes of administration Ocular drug delivery 
29
 
OCULAR SUSTAINED DRUG DELIVERY 
SYSTEMS  
In the novel drug delivery system various approaches 
like In situ gelling, use of mucoadhesive polymers, 
polymer coated Nanoparticles and Liposomal 
formulations are used. These delivery systems delay the 
elimination of active ingredient from eye and also 
improve corneal penetration of drug molecule 
34
.  
Novel ocular drug delivery systems 
1. Liposome:  
Liposome is biocompatible and biodegradable lipid 
vesicles made up of natural lipids and about 25-10,000 
nm in diameter. They are having an intimate contact 
with the corneal and conjunctiva surfaces which is 
desirable for drugs that are poorly absorbed, the drugs 
with low partition coefficient, poor solubility or those 
with medium to high molecular weights and thus 
increases the probability of ocular drug absorption
35
. 
The corneal epithelium is thinly coated with negatively 
charged mucin to which the positive charged surface of 
the liposome may bind. Formulated and evaluated soft 
contact lenses coated with ciprofloxacin entrapped in 
liposome.  
2. Implants:  
For chronic ocular diseases like cytomegalovirus 
retinitis, implants are effective drug delivery system. 
Earlier non biodegradable polymers were used but they 
needed surgical procedures for insertion and removal. 
Presently biodegradable polymers such as Poly Lactic 
Acid are safe and effective to deliver drugs in the 
vitreous cavity and show no toxic signs 
36
.  
3. Dendrimers: 
The majorities of topically applied ocular drug-delivery 
systems are formulated either as solutions, ointments, or 
suspensions and suffer from various disadvantages such 
as quick elimination from the precorneal region, poor 
bioavailability, or failure to deliver the drug in a 
sustained fashion. Several research advances have been 
made in ocular drug delivery systems by using 
specialized delivery systems such as polymers, 
liposomes, or dendrimers to overcome some of these 
disadvantages. Ideal ocular drug-delivery systems 
should be nonirritating, sterile, isotonic, biocompatible, 
and biodegradable. The viscosity of the final product 
should be optimized so that the dosage form does not 
run out of the eye. Dendrimers provide solutions to some 
complex delivery problems for ocular drug delivery
37
. 
Some recent research efforts in dendrimers for ocular 
drug delivery include PAMAM dendrimers that were 
studied by Vandamme and Brobeck as ophthalmic 
vehicles for controlled delivery of pilocarpine and 
tropicamide to the eye. PAMAM dendrimers with 
carboxylic or hydroxyl surface groups, have been 
reported in improving residence time and enhancing 
bioavailability of pilocarpine in the eye. In the New 
Zealand albino rabbit model, the residence time of 
pilocarpine in the eye was increased by using 
dendrimers with carboxylic or hydroxyl surface groups. 
These surface-modified dendrimers were predicted to 
enhance pilocarpine bioavailability. 
4. Nanotechnology based ocular drug delivery:  
In a last few decades, many approaches have been 
utilized for the treatment of ocular diseases 
38
. 
Nanotechnology based ophthalmic formulations are one 
of the approaches which is currently being pursued for 
both anterior, as well as posterior segment drug delivery. 
Nanotechnology based systems with an appropriate 
particle size can be designed to ensure low irritation, 
adequate bioavailability, and ocular tissue compatibility. 
Several nanocarriers, such as nanoparticles, 
nanosuspensions, liposome’s, nanomicelles and 
dendrites have been developed for ocular drug delivery 
39
. Some of them have shown promising results for 
improving ocular bioavailability. 
4.1 Nanosuspensions:  
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Nan suspensions have emerged as a promising strategy 
for the efficient delivery of hydrophobic drugs because 
they enhanced not only the rate and extent of ophthalmic 
drug absorption but also the intensity of drug action with 
significant extended duration of drug effect 
40
. For 
commercial preparation of nanosuspensions, techniques 
like media milling and high pressure homogenization 
have been used. The higher drug level in the aqueous 
humor was reported using Eudragit RS 100 
nanosuspensions for the ophthalmic controlled delivery 
of ibuprofen. 
4.2 Nanoparticles:  
Nanoparticles are colloidal carriers with a size range of 
10 to 1000 nm. For ophthalmic delivery, nanoparticles 
are generally composed of lipids, proteins, natural or 
synthetic polymers such as albumin, sodium alginate, 
chitosan, poly (lactide-co-glycolide) (PLGA), polylactic 
acid (PLA) and polycaprolactone. Drug loaded 
nanoparticles can be nanocapsules or nanospheres. In 
nanocapsules, drug is enclosed inside the polymeric 
shell while in nanospheres; drug is uniformly distributed 
throughout polymeric matrix 
41
. From past few decades, 
nanoparticles have gained attention for ocular drug 
delivery and several researchers have made attempts to 
develop drug loaded nanoparticles for delivery to both 
anterior and posterior ocular tissues.  
4.3 Niosomes: 
These are bilayered, lamellar structures primarily 
composed of non ionic surfactants and a rigidizing agent 
which are hydrated by different methods in order to form 
a vesicle. They are either unilamellar or multilamellar 
enclosing an aqueous compartment. Being amphiphilic 
in nature, the non ionic surfactants are known to possess 
the ability to self assemble. Critical parameters in 
niosome preparation govern the formation of vesicular 
structures instead of micelles
42, 43
. The surfactants being 
non-ionic in nature do not cause any irritation to the 
ocular tissue and their ability to act as penetration 
enhancers can also be exploited. 
Conventional ocular drug delivery systems 
Topical drop instillation into the lower precorneal pocket 
is a patient compliant and widely recommended route of 
drug administration. However, most of the topically 
administered dose is lost due to reflux blinking and only 
20% of instilled dose is retained in the precorneal pocket 
44
. Concentration of drug available in the precorneal area 
acts as a driving force for its passive diffusion across 
cornea. However, for efficient ocular drug delivery with 
eye drops, high corneal permeation with longer drug 
cornea contact time is required. Several efforts have 
been made toward improving precorneal residence time 
and corneal penetration 
45
. To improve corneal 
permeation iontophoresis, prodrugs, ion-pair forming 
agents and cyclodextrins are employed.  
1. Topical liquid/solution eye drops:  
Topical drops are the most convenient, safe, 
immediately active, patient compliant and non-invasive 
mode of ocular drug administration. An eye drop 
solution provides a pulse drug permeation post topical 
drop instillation, after which its concentration rapidly 
declines. The kinetics of drug concentration decline may 
follow an approximate first order. Therefore to improve 
drug contact time, permeation and ocular bioavailability; 
various additives may be added to topical eye drops such 
as viscosity enhancers, permeation enhancers and 
cyclodextrins 
46
.  
2. Emulsions:  
An emulsion based formulation approach offers an 
advantage to improve both solubility and bioavailability 
of drugs. There are two types of emulsions which are 
commercially exploited as vehicles for active 
pharmaceuticals: oil in water (o/w) and water in oil 
(w/o) emulsion systems. For ophthalmic drug delivery, 
o/w emulsion is common and widely preferred over w/o 
system. The reasons include less irritation and better 
ocular tolerance of o/w emulsion 
47
.  
3. Suspensions:  
Suspensions are another class of non-invasive ocular 
topical drop drug carrier systems. Suspension may be 
defined as dispersion of finely divided insoluble API in 
an aqueous solvent consisting of a suitable suspending 
and dispersing agent. In other words, the carrier solvent 
system is a saturated solution of API. Suspension 
particles retain in precorneal pocket and thereby improve 
drug contact time and duration of action relative to drug 
solution. Duration of drug action for suspension is 
particle size dependent. Smaller size particle replenishes 
the drug absorbed into ocular tissues from precorneal 
pocket 
48
. While on the other hand, larger particle size 
helps retain particles for longer time and slow drug 
dissolution
.
 Thus, an optimal particle size is expected to 
result in optimum drug activity. Several suspension 
formulations are marketed worldwide to treat ocular 
bacterial infections. TobraDex suspension is one of the 
widely recommended commercial products for subjects 
responding to steroid therapy.  
CONCLUSION 
Finally I concluded that a novel approaches on ocular 
drug delivery system was developing the ophthalmic 
solutions are easy because we can easily target the eye to 
treat ocular diseases with wide variety of novel 
approaches.  Progress in the field of ocular drug delivery 
has been established recently with controlled loading 
and sustained release. Hence, effective drug delivery and 
targeting is faced by challenges to overcome these 
barriers as a conventional drug delivery system. 
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